Latigo Biotherapeutics Inc.

LTGO

NASDAQHealthcareMedical - Pharmaceuticals

GoAI で開く

前日終値

$22.55

−$1.38 · -5.77%

9月18日 16:00 ET

企業プロフィール

会社ウェブサイト

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

業界: Medical - Pharmaceuticals
セクター: Healthcare
本社: US
最高経営責任者（CEO）: Nima Farzan
上場以来: 2026年8月7日
従業員: 59

市場での位置

日中レンジ

現在 $22.55

$22.21$24.50

52週レンジ

現在 $22.55

$17.22$25.93

始値: $24.18
前日終値: $23.93
出来高: 148.82万; 4.03× 平均
平均出来高: 36.96万; 1日平均出来高
時価総額: 13.56億 USD
ベータ: 0; 市場参照 1
50日平均: $21.7727; 平均以上（+3.57%）
200日平均: $21.7727; 平均以上（+3.57%）

アナリスト評価

第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。

アナリストの目標株価

平均目標

$52.25

上昇余地（131.71%）

過去 12 か月12か月の予測最高：$73.00平均：$52.25最低：$36.00

LTGO ニュース

defenseworld.net2026年9月9日

Latigo Biotherapeutics, Inc.’s Quiet Period Will End on September 16th (NASDAQ:LTGO)

Latigo Biotherapeutics' (NASDAQ: LTGO - Get Free Report) quiet period will expire on Wednesday, September 16th. Latigo Biotherapeutics had issued 19,200,000 shares in its public offering on August 7th. The total size of…

ソースを読む

globenewswire.com2026年9月3日

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Completed upsized initial public offering, including full exercise of the underwriters' option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund…

ソースを読む

247wallst.com2026年8月13日

Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public

Latigo Biotherapeutics (NASDAQ:LTGO) arrived on public markets with the kind of reception biotech bankers dream about.

ソースを読む

defenseworld.net2026年8月11日

Latigo Biotherapeutics (NASDAQ:LTGO) Director James Tananbaum Buys 140,000 Shares

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) Director James Tananbaum bought 140,000 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an…

ソースを読む

defenseworld.net2026年8月11日

Latigo Biotherapeutics (NASDAQ:LTGO) Major Shareholder Foresite Capital Management V, Acquires 140,000 Shares

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) major shareholder Foresite Capital Management V, bought 140,000 shares of Latigo Biotherapeutics stock in a transaction on Monday, August 10th. The shares…

ソースを読む

businesswire.com2026年7月29日

Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines, today announced the publication of positive…

ソースを読む